|Description||Reboxetine, also called as Vestra, 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate, exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. Ti is a selective norepinephrine reuptake inhibitor used in the treatment of clinical depression, panic disorder and ADD/ADHD which has been approved for treatment of major depression. In vitro: it inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine and does not inhibit the activity of the following isozymes of cytochrome P450: CYP1A2, CYP2C9, CYP2C19, and CYP2E1; In vivo: Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.Besides, it inhibits both CYP2D6 and CYP3A4 with low binding affinities, but has shown no effect on the in vivo clearance of drugs metabolized by these enzymes. Inhibits (±)-epibatidine-induced Ca(2+) influx in human (h) muscle embryonic (hα1β1γδ) and adult (hα1β1εδ) AChRs in a non-competitive manner , with potencies IC50= 3.86±0.49 and 1.92±0.48 μM, respectively.|
|Appearance||Off-White to Pale Beige Solid|
|Synonyms||(2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; reboxetine; reboxetine mesylate; Vestra; Reboxetine; Edronax (TN); AC1L2RJ0; Vestra; Reboxetine (INN); D08472; 98769-81-4; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; 71620-89-8; 98769-83-6; (R,R)-Reboxetine; eboxetine [INN:BAN]; SCHEMBL34533; CHEMBL383921; DTXSID1048257; HSDB 7701; ZINC3996032; AKOS015966368; AJ-47614; AN-34535; FT-0653731; FT-0699742; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; (2R)-2-[(R)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Morpholine,2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; 41X|
|Solubility||In water, 433 mg/L at 25ºC|
|Application||A selective norepinephrine reuptake inhibitor used in the treatment of clinical depression, panic disorder and ADD/ADHD, has been approved for treatment of major depression;|
|Quality Standard||In-house standard|
Bafetinib is a potent and selective dual Bcr-Abl/Lyn inhibitor, but it does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and ...
Pentagastrin is a synthetic polypeptide used as a diagnostic aid for evaluation of gastric acid secretory function
BD 1008 dihydrobromide
BD 1008 dihydrobromide is a potent and selective σ receptor antagonist displaying 4-fold selectivity for σ1 over σ2. BD-1008 attenuates the toxicity and stimula...
FK 960 is a somatostatin receptor agonist and a 5-HT agonist activating both serotonin and somatostatin production as a cognitive enhancer. The phase II clinica...
(S)-4-Carboxyphenylglycine has been found to be a competitive group I metabotropic glutamate receptor antagonist(S)-4-Carboxyphenylglycine has been found to be ...
KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.
Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...
Doramectin is a derivative of ivermectin, which is an anthelmintic. Doramectin is an antiparasitic antibiotic.